Diabetes Care:有效的服药依从性自我报告利于2型糖尿病管理

2012-12-11 Diabetes Care Diabetes Care

  来自美国的一项研究结果,支持易于管理的自我报告对改善糖尿病患者服药依从性的有效性。在1个月内,按百分比计算评级的服药依从性,与药物事件监视系统(MEMS)和糖化血红蛋白之(HbA1c)间显示最强的关联;而在那些需要报告错误剂量的受试者中,有较弱的关联。为期一周、要求受访者记录错误剂量数量的自我评价和测量,表现为易于受到抑郁症严重程度的影响而产生偏差。研究在2012年11月30日在线发表于《糖尿




  来自美国的一项研究结果,支持易于管理的自我报告对改善糖尿病患者服药依从性的有效性。在1个月内,按百分比计算评级的服药依从性,与药物事件监视系统(MEMS)和糖化血红蛋白之(HbA1c)间显示最强的关联;而在那些需要报告错误剂量的受试者中,有较弱的关联。为期一周、要求受访者记录错误剂量数量的自我评价和测量,表现为易于受到抑郁症严重程度的影响而产生偏差。研究在2012年11月30日在线发表于《糖尿病护理》(Diabetes Care)杂志。

  该研究旨在评估糖尿病患者自我报告以评价服药依从性的有效性,以及评估抑郁症对这些自我报告有效性的影响。

  研究共纳入170例患有2型糖尿病、接受口服药物治疗的成年受试者,完成一组在变化反应尺度和时间框架条件下的服药依从性自我报告,接受抑郁症的结构化临床晤谈,并提供了血液样本以检测HbA1c,作为干预研究筛查的一个组成部分。其中对于患有临床显著抑郁症和HbA1c≥7.0%的一个受试者样本亚群,接受MEMS瓶盖以记录服药依从性。分析评估依从性测量和HbA1c、子样本中MEMS之间的关系。调节线性回归分析评估抑郁症的严重程度是否改变依从性与HbA1c的关系。

  结果表明,受试者[N=170,57%为男性,81%是白人,平均糖化血红蛋白为8.3%(SD,1.7)]的自我报告依从性与较低的HbA1c显著相关(r=-0.18至-0.28,P<0.03)。在子样本中(N=88),所有的自我报告均与MEMS测量的依从性相关(r=0.35至0.55,P≤0.001)。抑郁症显著减弱了3/6个自我报告和糖化血红蛋白之间的关系;在抑郁水平较高时,依从性与HbA1c的相关性变为不显著。
 


OBJECTIVE 
To assess the validity of self-report measures of diabetes medication adherence and evaluate the effect of depression on the validity of these reports.
RESEARCH DESIGN AND METHODS 
Adults with type 2 diabetes, treated with oral medications, completed a set of medication adherence self-reports that varied response scales and time frames, were administered structured clinical interviews for depression, and provided blood samples for HbA1c as part of a screening for an intervention study. A subsample of participants with HbA1c ≥7.0% and clinically significant depression received Medication Event Monitoring System (MEMS) bottle caps to record adherence. Analyses examined relationships between adherence measures and HbA1c and, in the subsample, MEMS. Moderated linear regression evaluated whether depression severity modified relationships with HbA1c.
RESULTS 
Participants’ (n = 170, 57% men, 81% white, mean HbA1c = 8.3% [SD, 1.7]) adherence self-reports were significantly (r = −0.18 to −0.28; P < 0.03) associated with lower HbA1c. In the subsample (n = 88), all self-reports were significantly (r = 0.35 to 0.55; P ≤ 0.001) associated with MEMS-measured adherence. Depression significantly moderated the relationship between three of six self-reports and HbA1c; at high levels of depression, associations with HbA1c became nonsignificant.
CONCLUSIONS 
Results support the validity of easily administered self-reports for diabetes medication adherence. One-month, percentage-based ratings of adherence had the strongest associations with MEMS and HbA1c; those requiring the report of missed doses had weaker associations. One-week self-ratings and measures that require respondents to record the number of missed doses appear to be vulnerable to bias from depression severity.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636602, encodeId=d1f4163660214, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 11 07:00:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901032, encodeId=82bd1901032f1, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759224, encodeId=38f21e592246c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 22 13:00:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763895, encodeId=06271e6389575, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Sun Sep 01 02:00:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931683, encodeId=54c3193168358, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Oct 25 18:00:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5308, encodeId=40c9530819, content=That's a posting full of insihgt!, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Mhariel, createdTime=Fri Jan 04 23:30:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319234, encodeId=4292131923498, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Dec 12 15:00:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636602, encodeId=d1f4163660214, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 11 07:00:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901032, encodeId=82bd1901032f1, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759224, encodeId=38f21e592246c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 22 13:00:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763895, encodeId=06271e6389575, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Sun Sep 01 02:00:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931683, encodeId=54c3193168358, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Oct 25 18:00:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5308, encodeId=40c9530819, content=That's a posting full of insihgt!, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Mhariel, createdTime=Fri Jan 04 23:30:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319234, encodeId=4292131923498, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Dec 12 15:00:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636602, encodeId=d1f4163660214, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 11 07:00:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901032, encodeId=82bd1901032f1, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759224, encodeId=38f21e592246c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 22 13:00:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763895, encodeId=06271e6389575, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Sun Sep 01 02:00:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931683, encodeId=54c3193168358, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Oct 25 18:00:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5308, encodeId=40c9530819, content=That's a posting full of insihgt!, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Mhariel, createdTime=Fri Jan 04 23:30:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319234, encodeId=4292131923498, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Dec 12 15:00:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636602, encodeId=d1f4163660214, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 11 07:00:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901032, encodeId=82bd1901032f1, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759224, encodeId=38f21e592246c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 22 13:00:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763895, encodeId=06271e6389575, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Sun Sep 01 02:00:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931683, encodeId=54c3193168358, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Oct 25 18:00:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5308, encodeId=40c9530819, content=That's a posting full of insihgt!, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Mhariel, createdTime=Fri Jan 04 23:30:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319234, encodeId=4292131923498, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Dec 12 15:00:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636602, encodeId=d1f4163660214, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 11 07:00:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901032, encodeId=82bd1901032f1, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759224, encodeId=38f21e592246c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 22 13:00:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763895, encodeId=06271e6389575, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Sun Sep 01 02:00:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931683, encodeId=54c3193168358, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Oct 25 18:00:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5308, encodeId=40c9530819, content=That's a posting full of insihgt!, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Mhariel, createdTime=Fri Jan 04 23:30:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319234, encodeId=4292131923498, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Dec 12 15:00:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1636602, encodeId=d1f4163660214, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 11 07:00:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901032, encodeId=82bd1901032f1, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759224, encodeId=38f21e592246c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 22 13:00:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763895, encodeId=06271e6389575, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Sun Sep 01 02:00:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931683, encodeId=54c3193168358, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Oct 25 18:00:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5308, encodeId=40c9530819, content=That's a posting full of insihgt!, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Mhariel, createdTime=Fri Jan 04 23:30:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319234, encodeId=4292131923498, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Dec 12 15:00:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
    2013-01-04 Mhariel

    That's a posting full of insihgt!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1636602, encodeId=d1f4163660214, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 11 07:00:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901032, encodeId=82bd1901032f1, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759224, encodeId=38f21e592246c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 22 13:00:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763895, encodeId=06271e6389575, content=<a href='/topic/show?id=8dce86164b8' target=_blank style='color:#2F92EE;'>#自我报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86164, encryptionId=8dce86164b8, topicName=自我报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f8137597854, createdName=12498aa2m74(暂无昵称), createdTime=Sun Sep 01 02:00:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931683, encodeId=54c3193168358, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Oct 25 18:00:00 CST 2013, time=2013-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5308, encodeId=40c9530819, content=That's a posting full of insihgt!, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Mhariel, createdTime=Fri Jan 04 23:30:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319234, encodeId=4292131923498, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Dec 12 15:00:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
    2012-12-12 fyxzlh

相关资讯

难治性高血压或许并非真难治

 纠正难治性高血压药物治疗的不规范之处   常用降压药物使用不尽合理   药物选择不当 高血压发病机制存在异质性, 在用药选择时应针对患者的发病机制, 坚持个体化原则。   对于容量负荷增加、 交感兴奋、 肾素-血管紧张素系统激活的患者, 须针对性用药或有侧重地增加某类药物的剂量。例如高血压伴慢性肾脏疾病、 糖尿

AHA2012:治疗急性心肾综合征超滤治疗不如药物治疗

  美国心脏协会(AHA)年会上公布的一项大型多中心随机研究显示,在利尿剂治疗有效的合并心肾综合征的急性失代偿性心力衰竭住院患者中,机械性静脉-静脉超滤的疗效不如药物治疗。   这项急性失代偿性心力衰竭心肾抢救研究(CARRESS-HF)由明尼阿波里斯市亨内平县医疗中心的Bradley A. Bart博士及其同事进行,共纳入188例利尿剂治疗有效的患者。患者被随机分成2组,一组接受阶梯式药物治疗

AHA 2012:治疗急性心肾综合征超滤治疗不如药物治疗

  美国心脏协会(AHA)年会上公布的一项大型多中心随机研究显示,在利尿剂治疗有效的合并心肾综合征的急性失代偿性心力衰竭住院患者中,机械性静脉-静脉超滤的疗效不如药物治疗。   这项急性失代偿性心力衰竭心肾抢救研究(CARRESS-HF)由明尼阿波里斯市亨内平县医疗中心的Bradley A. Bart博士及其同事进行,共纳入188例利尿剂治疗有效的患者。患者被随机分成2组,一组接受阶梯式药物治疗

随机双盲研究:枕部神经刺激缓解药物治疗无效偏头痛

美国头痛学会年会上报告的一项针对偏头痛药物治疗无应答患者的随机双盲试验显示,枕部神经刺激可使慢性偏头痛缓解。 该研究中,费城杰佛逊头痛中心的研究者纳入125例每月至少15天有头痛发作、至少3种预防性药物治疗失败并发生中度头痛相关障碍的慢性、难治性偏头痛患者。其疼痛必须在10 cm视觉模拟量表中标注在6 cm以上,且疼痛局限于头后部或起源于颈部区域。不要求患者既往对枕部神经阻滞有应答,Silbers

NEJM:射频消融治疗房颤与药物治疗效果相似

  射频(RF)消融作为一线治疗阵发性心房颤动(AF)是否比药物控制心率治疗更有效?一项随机研究显示,2年随访期间射频消融组阵发性房颤患者的房颤负担总体降幅与药物治疗组相似,该研究在线发表于10月25日的《新英格兰医学杂志》上。   这项MANTA-PAF研究从丹麦、芬兰、德国和瑞典的中心纳入294例既往未接受过消融治疗或ⅠC类或Ⅲ类抗心律失常药物治疗的≤70岁(平均55岁)阵发性房颤患者。略多

伊伐布雷定:减慢心率又添适应证

    2012年2月9日欧洲药品监管局(EMEA)正式批准单纯降低心率的新药伊伐布雷定用于合并收缩功能异常的慢性心力衰竭(心衰)治疗。该适应证的获批主要基于SHIFT研究结果,即伊伐布雷定在β受体阻滞剂等传统药物治疗的基础上可使心衰患者的主要终点(心血管死亡和心衰恶化住院)显著降低l8%.心衰死亡风险显著降低26%。此前,伊伐布雷定在2005和2009年分别在欧洲获